Skip to main content

beclometasone dipropionate/formoterol fumarate (Fostair®)

 

Status: Medicine does not meet criteria for AWMSG assessment

Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.

Medicine details

Medicine name beclometasone dipropionate/formoterol fumarate (Fostair®)
Formulation 100 micrograms/6 micrograms inhalation solution
Reference number 1848
Indication

Regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist; or patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists

Company Chiesi Ltd
BNF chapter Respiratory system
Assessment type N/A
Status Medicine does not meet criteria for AWMSG assessment
Date of issue 26/07/2013
Follow AWTTC: